Bioventus Inc (BVS)

$7.47

+0.02

(+0.27%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $7.32
    $7.57
    $7.47
    downward going graph

    2.01%

    Downside

    Day's Volatility :3.3%

    Upside

    1.32%

    downward going graph
  • $2.82
    $7.67
    $7.47
    downward going graph

    62.25%

    Downside

    52 Weeks Volatility :63.23%

    Upside

    2.61%

    downward going graph

Returns

PeriodBioventus IncSector (Health Care)Index (Russel 2000)
3 Months
87.19%
6.5%
0.0%
6 Months
64.82%
7.1%
0.0%
1 Year
125.08%
9.8%
0.0%
3 Years
-55.47%
14.2%
-20.2%

Highlights

Market Capitalization
482.5M
Book Value
$2.69
Earnings Per Share (EPS)
-0.33
PEG Ratio
2.14
Wall Street Target Price
8.5
Profit Margin
-4.14%
Operating Margin TTM
4.34%
Return On Assets TTM
1.52%
Return On Equity TTM
-11.87%
Revenue TTM
522.7M
Revenue Per Share TTM
8.3
Quarterly Revenue Growth YOY
8.7%
Gross Profit TTM
302.7M
EBITDA
42.6M
Diluted Eps TTM
-0.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.28
EPS Estimate Next Year
0.46
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
0.05

Analyst Recommendation

Buy
    71%Buy
    14%Hold
    14%Sell
Based on 7 Wall street analysts offering stock ratings for Bioventus Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
5
Hold
1
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 13.79%

Current $7.47
Target $8.50

Company Financials

FY18Y/Y Change
Revenue
319.2M
↑ 25.83%
Net Income
-12.2M
↓ 64.21%
Net Profit Margin
-3.82%
↑ 9.63%
FY19Y/Y Change
Revenue
340.1M
↑ 6.57%
Net Income
6.9M
↓ 156.12%
Net Profit Margin
2.01%
↑ 5.83%
FY20Y/Y Change
Revenue
321.2M
↓ 5.58%
Net Income
16.4M
↑ 139.54%
Net Profit Margin
5.11%
↑ 3.1%
FY21Y/Y Change
Revenue
430.9M
↑ 34.17%
Net Income
9.6M
↓ 41.59%
Net Profit Margin
2.22%
↓ 2.89%
FY22Y/Y Change
Revenue
512.1M
↑ 18.85%
Net Income
-213.4M
↓ 2326.07%
Net Profit Margin
-41.67%
↓ 43.89%
FY23Y/Y Change
Revenue
512.3M
↑ 0.04%
Net Income
-156.2M
↓ 26.79%
Net Profit Margin
-30.49%
↑ 11.18%
Q4 FY22Q/Q Change
Revenue
125.8M
↓ 8.2%
Net Income
-44.9M
↓ 1513.32%
Net Profit Margin
-35.66%
↓ 37.98%
Q1 FY23Q/Q Change
Revenue
119.1M
↓ 5.38%
Net Income
-100.0M
↑ 122.89%
Net Profit Margin
-84.01%
↓ 48.35%
Q2 FY23Q/Q Change
Revenue
137.1M
↑ 15.13%
Net Income
-3.7M
↓ 96.32%
Net Profit Margin
-2.69%
↑ 81.32%
Q3 FY23Q/Q Change
Revenue
120.8M
↓ 11.87%
Net Income
-7.3M
↑ 98.4%
Net Profit Margin
-6.05%
↓ 3.36%
Q4 FY23Q/Q Change
Revenue
135.4M
↑ 12.11%
Net Income
-6.1M
↓ 16.53%
Net Profit Margin
-4.5%
↑ 1.55%
Q1 FY24Q/Q Change
Revenue
129.5M
↓ 4.41%
Net Income
-4.6M
↓ 25.03%
Net Profit Margin
-3.53%
↑ 0.97%
FY18Y/Y Change
Total Assets
442.7M
↓ 9.16%
Total Liabilities
297.5M
↑ 0.83%
FY19Y/Y Change
Total Assets
472.4M
↑ 6.7%
Total Liabilities
326.8M
↑ 9.86%
FY20Y/Y Change
Total Assets
494.5M
↑ 4.67%
Total Liabilities
350.3M
↑ 7.2%
FY21Y/Y Change
Total Assets
1.2B
↑ 147.92%
Total Liabilities
692.1M
↑ 97.56%
FY22Y/Y Change
Total Assets
1.4B
↑ 11.97%
Total Liabilities
1.0B
↑ 49.16%
FY23Y/Y Change
Total Assets
810.9M
↓ 40.92%
Total Liabilities
589.8M
↓ 42.87%
Q4 FY22Q/Q Change
Total Assets
1.4B
↓ 13.52%
Total Liabilities
1.0B
↓ 2.54%
Q1 FY23Q/Q Change
Total Assets
887.4M
↓ 35.35%
Total Liabilities
647.0M
↓ 37.32%
Q2 FY23Q/Q Change
Total Assets
837.0M
↓ 5.68%
Total Liabilities
603.6M
↓ 6.71%
Q3 FY23Q/Q Change
Total Assets
811.1M
↓ 3.09%
Total Liabilities
584.6M
↓ 3.14%
Q4 FY23Q/Q Change
Total Assets
810.9M
↓ 0.02%
Total Liabilities
589.8M
↑ 0.88%
Q1 FY24Q/Q Change
Total Assets
794.2M
↓ 2.06%
Total Liabilities
576.8M
↓ 2.2%
FY18Y/Y Change
Operating Cash Flow
45.2M
↑ 138.83%
Investing Cash Flow
-6.1M
↓ 89.86%
Financing Cash Flow
-13.3M
↓ 142.42%
FY19Y/Y Change
Operating Cash Flow
40.7M
↓ 9.9%
Investing Cash Flow
-7.9M
↑ 29.68%
Financing Cash Flow
-11.0M
↓ 17.39%
FY20Y/Y Change
Operating Cash Flow
71.8M
↑ 76.35%
Investing Cash Flow
-20.5M
↑ 159.1%
Financing Cash Flow
-29.6M
↑ 170.01%
FY21Y/Y Change
Operating Cash Flow
23.0M
↓ 67.98%
Investing Cash Flow
-283.8M
↑ 1284.2%
Financing Cash Flow
273.4M
↓ 1024.52%
Q4 FY22Q/Q Change
Operating Cash Flow
5.2M
↓ 848.07%
Investing Cash Flow
33.5M
↓ 159.47%
Financing Cash Flow
-5.4M
↓ 110.74%
Q1 FY23Q/Q Change
Operating Cash Flow
2.5M
↓ 52.52%
Investing Cash Flow
-15.1M
↓ 144.97%
Financing Cash Flow
27.4M
↓ 603.49%
Q2 FY23Q/Q Change
Operating Cash Flow
10.8M
↑ 333.53%
Investing Cash Flow
33.5M
↓ 322.35%
Financing Cash Flow
-62.2M
↓ 327.35%

Technicals Summary

Sell

Neutral

Buy

Bioventus Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bioventus Inc
Bioventus Inc
33.04%
64.82%
125.08%
-55.47%
-61.22%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bioventus Inc
Bioventus Inc
9.44
NA
2.14
0.28
-0.12
0.02
NA
2.69
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bioventus Inc
Bioventus Inc
Buy
$482.5M
-61.22%
9.44
-4.14%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Bioventus Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 135.42M → 129.45M (in $), with an average decrease of 4.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -7.30M → -4.57M (in $), with an average increase of 26.6% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 124.4%

Institutional Holdings

  • Essex Woodlands Health Ventures

    20.40%

  • Juniper Investment Co, LLC

    10.71%

  • Nantahala Capital Management, LLC

    9.10%

  • Vanguard Group Inc

    1.91%

  • Millennium Management LLC

    0.86%

  • BlackRock Inc

    0.83%

Company Information

bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat

Organization
Bioventus Inc
Employees
995
CEO
Mr. Mark L. Singleton
Industry
Healthcare

Discover More

FAQs